Slupp332 and 5-Amino-1MQ: Liver, Adipocyte, and Mitochondrial Safety Endpoints for Combination Studies

Zero controlled human safety trials exist for either SLU-PP-332 or 5-Amino-1MQ as of 2026, yet capsule stacks combining both compounds are sold openly online, promoted with mouse-injection data and no validated organ toxicology. That gap between commercial availability and scientific evidence defines the central challenge when evaluating Slupp332 and 5-Amino-1MQ: liver, adipocyte, and mitochondrial safety endpoints for combination studies.

This article examines what is known, what is missing, and what rigorous preclinical and clinical safety programs would need to address before either compound, let alone both together, could be used with any meaningful confidence.

Key Takeaways

• SLU-PP-332 activates estrogen-related receptors (ERRα/β/γ) to drive mitochondrial biogenesis; 5-Amino-1MQ inhibits NNMT in adipose tissue to reduce fat mass, both effects are confirmed only in rodent models.
• No human pharmacokinetic, hepatotoxicity, or mitochondrial safety data exist for either compound as of late 2026.
• The quinolinium chemical class to which 5-Amino-1MQ belongs carries unresolved genotoxicity concerns; NNMT inhibition may also suppress 1-methylnicotinamide with hypothetical cardiovascular implications.
• Grey-market combination products rely entirely on animal injection data, providing no validated liver, adipocyte, or mitochondrial safety endpoints.
• Future development programs would require GLP-grade rodent toxicology covering hepatic enzymes, adipose morphology, mitochondrial function assays, and cardiovascular markers before any human trial could be justified.

Mechanisms Behind the Combination: What Each Compound Does

Understanding why researchers are interested in pairing these two agents requires a clear look at their individual mechanisms.

SLU-PP-332 is a synthetic pan-agonist of estrogen-related receptors. It simultaneously activates ERRα, ERRβ, and ERRγ, nuclear receptors that regulate oxidative phosphorylation and mitochondrial biogenesis. In diet-induced obese mouse models, SLU-PP-332 increased expression of oxidative metabolic genes in skeletal muscle, improved running endurance, reduced fat mass, and enhanced insulin sensitivity. Critically, these results came from injected doses; oral bioavailability is acknowledged to be poor even by vendor documentation.

5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme highly expressed in white adipose tissue. NNMT methylates nicotinamide, diverting it from NAD+ biosynthesis. When NNMT is blocked, more substrate flows back toward NAD+, shifting adipocyte energy balance and reducing white adipose mass in obese rodent models. The compound is not FDA-approved, does not appear in DailyMed, and has no registered human clinical trials as of 2026.

"The mechanistic rationale for combining an ERR pan-agonist with an NNMT inhibitor is scientifically coherent, both touch NAD-related and mitochondrial pathways, but mechanistic plausibility is not the same as demonstrated safety."

Both compounds are frequently mis-marketed as peptides. They are small molecules. That distinction matters for predicting metabolism, hepatic clearance, and potential drug interactions.

Liver, Adipocyte, and Mitochondrial Safety Endpoints: What the Data Actually Show

When evaluating Slupp332 and 5-Amino-1MQ: liver, adipocyte, and mitochondrial safety endpoints for combination studies, the honest summary is brief: rodent data shows no acute organ failure at tested doses, and that is largely where the evidence stops.

Hepatic Safety Endpoints

No controlled study has measured alanine aminotransferase (ALT), aspartate aminotransferase (AST), or liver histology in animals or humans after either compound at doses translatable to human use. Key gaps include:

• Transaminase monitoring, no baseline or post-exposure enzyme data in published literature
• Lipid droplet accumulation, NNMT plays a role in hepatic lipid metabolism; inhibition effects on liver steatosis are uncharacterized
• Oxidative stress in hepatocytes, ERR activation increases reactive oxygen species (ROS) alongside mitochondrial biogenesis; liver-specific ROS burden has not been quantified

For researchers exploring SS-31 mitochondrial research as a reference point, SS-31's hepatic profile is far better characterized than either compound discussed here, underscoring how immature the SLU-PP-332 and 5-Amino-1MQ safety literature remains.

Adipocyte Safety Endpoints

5-Amino-1MQ targets adipose tissue directly, making adipocyte viability a first-order concern. Missing data include:

The concern is not just toxicity but dysfunction: excessive or off-target NNMT inhibition could disrupt adipokine signaling, with downstream effects on insulin sensitivity and inflammation that no current study has addressed.

Mitochondrial Safety Endpoints

SLU-PP-332's core mechanism, upregulating mitochondrial biogenesis via ERR activation, is also its primary safety question. More mitochondria are not unconditionally beneficial. Uncoupled or dysfunctional mitochondria generate excess ROS. No study has measured:

• Mitochondrial membrane potential under prolonged ERR activation
• Oxygen consumption rate in non-muscle tissues (especially liver)
• Mitophagy regulation or mitochondrial quality control markers

Resources on SS-31 peptide benefits illustrate that mitochondria-targeting compounds require specific assay frameworks; those frameworks simply do not exist yet for SLU-PP-332.

Combination Safety Concerns and Exposure Controls

Evaluating Slupp332 and 5-Amino-1MQ: liver, adipocyte, and mitochondrial safety endpoints for combination studies as a stack introduces additive and potentially synergistic unknowns.

Genotoxicity and Chemical Class Risk

The quinolinium scaffold in 5-Amino-1MQ is structurally related to known mutagens. Genotoxicity for 5-Amino-1MQ itself has not been formally confirmed or ruled out. Any responsible development program would require an Ames test and in vitro chromosomal aberration assay as first-line screening before advancing to organ-specific endpoints.

1-Methylnicotinamide Suppression

NNMT inhibition reduces 1-methylnicotinamide (1-MNA), a metabolite with proposed cardioprotective and anti-inflammatory properties. Chronic suppression of 1-MNA is a hypothetical cardiovascular risk that has not been evaluated in any controlled model, and it represents a distinct concern from liver or mitochondrial toxicity.

What a Responsible Safety Program Would Require

Before any human combination study could be justified, reviewers and mechanistic analyses converge on a minimum preclinical package:

1. GLP rodent toxicology, 28-day and 90-day repeat-dose studies with full histopathology including liver, kidney, heart, and adipose
2. Mitochondrial function assays, Seahorse respirometry in hepatocytes and adipocytes exposed to both compounds individually and combined
3. Hepatic enzyme panels, Serial ALT, AST, alkaline phosphatase, and bilirubin at multiple dose levels
4. Genotoxicity battery, Ames test, micronucleus assay
5. Cardiovascular markers, 1-MNA levels, echocardiography in rodent models
6. Human pharmacokinetic studies, Oral bioavailability, half-life, protein binding, and metabolite identification

For context on how peptide and small-molecule research stacks approach metabolic fat-loss endpoints more broadly, resources on tesa dosage for fat loss demonstrate that even well-studied compounds require robust dose-finding and monitoring before clinical use. Both SLU-PP-332 and 5-Amino-1MQ remain far behind that standard.

Grey-market products now combine 50 mg 5-Amino-1MQ with 1 mg SLU-PP-332 in a single capsule, labeled "not for human consumption." None of these products report GLP-grade toxicology, and all product descriptions draw on rodent injection data, a pharmacokinetic model that does not translate directly to human oral dosing. Interested readers can also review AOD 9604 price and research context as a comparison point for how even more established metabolic research compounds carry significant regulatory and data limitations.

Conclusion

The scientific case for combining SLU-PP-332 and 5-Amino-1MQ is mechanistically interesting: ERR pan-agonism plus NNMT inhibition could theoretically complement each other across mitochondrial and adipose metabolic pathways. However, the safety case does not exist yet. As of 2026, no human clinical data, no formal hepatic enzyme monitoring, no adipocyte viability assays, and no mitochondrial stress protocols have been published for either compound, individually or in combination.

Actionable next steps for researchers and clinicians:

• Treat any commercial combination product as entirely experimental with undetermined organ-specific risk.
• Prioritize genotoxicity screening for 5-Amino-1MQ given its quinolinium structure before any chronic exposure model.
• Design future preclinical programs to include liver histology, mitochondrial respirometry, adipose morphology, and 1-MNA cardiovascular monitoring as minimum endpoints.
• Consult resources on established mitochondria-targeting compounds, such as SS-31 elamipretide, to understand what a mature safety profile for a mitochondrial compound actually looks like.
• Do not conflate rodent injection efficacy data with human oral safety data; the two are categorically different.

The evidence gap is not a reason to dismiss future research into this combination, it is a precise map of what that research must address first.